These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 2965613

  • 21. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
    Diddens H, Niethammer D, Jackson RC.
    Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
    [Abstract] [Full Text] [Related]

  • 22. The effects of combined antifolates on inhibition of growth of murine leukemia cells cultured in vitro.
    Balińska M, Szablewska I, Janiszewska D, Bartuzi K, Pawełczak K.
    Acta Biochim Pol; 1997 Nov; 44(4):743-50. PubMed ID: 9584854
    [Abstract] [Full Text] [Related]

  • 23. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
    Habeck LL, Leitner TA, Shackelford KA, Gossett LS, Schultz RM, Andis SL, Shih C, Grindey GB, Mendelsohn LG.
    Cancer Res; 1994 Feb 15; 54(4):1021-6. PubMed ID: 8313357
    [Abstract] [Full Text] [Related]

  • 24. Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists.
    Chello PL, McQueen CA, DeAngelis LM, Bertino JR.
    Cancer Res; 1976 Jul 15; 36(7 PT 1):2442-9. PubMed ID: 1277151
    [Abstract] [Full Text] [Related]

  • 25. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
    Li WW, Tong WP, Bertino JR.
    Clin Cancer Res; 1995 Jun 15; 1(6):631-6. PubMed ID: 9816025
    [Abstract] [Full Text] [Related]

  • 26. Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine.
    Sirotnak FM, Moccio DM, Goutas LJ, Kelleher LE, Montgomery JA.
    Cancer Res; 1982 Mar 15; 42(3):924-8. PubMed ID: 7059991
    [Abstract] [Full Text] [Related]

  • 27. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
    Sanghani SP, Moran RG.
    Biochemistry; 1997 Aug 26; 36(34):10506-16. PubMed ID: 9265631
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
    Thorndike J, Gaumont Y, Kisliuk RL, Sirotnak FM, Murthy BR, Nair MG, Piper JR.
    Cancer Res; 1989 Jan 01; 49(1):158-63. PubMed ID: 2521177
    [Abstract] [Full Text] [Related]

  • 29. Mechanism of the induction of the differentiation of HL-60 leukemia cells by antifolates.
    Sokoloski JA, Beardsley GP, Sartorelli AC.
    Cancer Commun; 1989 Jan 01; 1(3):199-207. PubMed ID: 2700913
    [Abstract] [Full Text] [Related]

  • 30. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ, Smitskamp-Wilms E, Smid K, Pinedo HM, Jansen G.
    Cancer Res; 1999 Nov 01; 59(21):5529-35. PubMed ID: 10554030
    [Abstract] [Full Text] [Related]

  • 31. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor.
    O'Connor BM, Jackman AL, Crossley PH, Freemantle SE, Lunec J, Calvert AH.
    Cancer Res; 1992 Mar 01; 52(5):1137-43. PubMed ID: 1737372
    [Abstract] [Full Text] [Related]

  • 32. Effect of direct suppression of thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site on the interconversion of tetrahydrofolate cofactors to dihydrofolate by antifolates. Influence of degree of dihydrofolate reductase inhibition.
    Seither RL, Trent DF, Mikulecky DC, Rape TJ, Goldman ID.
    J Biol Chem; 1991 Mar 05; 266(7):4112-8. PubMed ID: 1825652
    [Abstract] [Full Text] [Related]

  • 33. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration.
    Jansen G, Barr H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Peters GJ, Assaraf YG.
    Mol Pharmacol; 1999 Apr 05; 55(4):761-9. PubMed ID: 10101035
    [Abstract] [Full Text] [Related]

  • 34. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells.
    Seither RL, Trent DF, Mikulecky DC, Rape TJ, Goldman ID.
    J Biol Chem; 1989 Oct 15; 264(29):17016-23. PubMed ID: 2529254
    [Abstract] [Full Text] [Related]

  • 35. Depletion of 5,10-methylenetetrahydrofolate and 10-formyltetrahydrofolate by methotrexate in cultured hepatoma cells.
    Rhee MS, Coward JK, Galivan J.
    Mol Pharmacol; 1992 Nov 15; 42(5):909-16. PubMed ID: 1435754
    [Abstract] [Full Text] [Related]

  • 36. Folate and antifolate pharmacology.
    Kamen B.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
    [Abstract] [Full Text] [Related]

  • 37. Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.
    Assaraf YG, Ifergan I, Kadry WN, Pinter RY.
    J Theor Biol; 2006 Jun 21; 240(4):637-47. PubMed ID: 16352313
    [Abstract] [Full Text] [Related]

  • 38. Biochemical pharmacology of the lipophilic antifolate, trimetrexate.
    Jackson RC, Fry DW, Boritzki TJ, Besserer JA, Leopold WR, Sloan BJ, Elslager EF.
    Adv Enzyme Regul; 1984 Jun 21; 22():187-206. PubMed ID: 6236675
    [Abstract] [Full Text] [Related]

  • 39. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
    Miyachi H, Takemura Y, Kobayashi H, Ando Y.
    Jpn J Cancer Res; 1997 Sep 21; 88(9):900-6. PubMed ID: 9369939
    [Abstract] [Full Text] [Related]

  • 40. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
    Faessel HM, Slocum HK, Rustum YM, Greco WR.
    Int J Oncol; 2003 Aug 21; 23(2):401-9. PubMed ID: 12851689
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.